نتایج جستجو برای: thalidomide

تعداد نتایج: 3195  

Journal: :International immunopharmacology 2013
Keyvan Amirshahrokhi

Thalidomide has been used in inflammatory and autoimmune disorders due to its anti-inflammatory activity. Paraquat (PQ) poisoning causes severe lung injury. PQ-induced pulmonary inflammation and fibrosis are due to its ability to induce oxidative stress, inflammatory and fibrotic reactions. This study was designed to evaluate the anti-inflammatory and anti-fibrotic effect of thalidomide on PQ-i...

Journal: :International journal of molecular medicine 2008
Toyotaka Iguchi Tomomi Yachide-Noguchi Yuichi Hashimoto Sawako Nakazato Morihiko Sagawa Yasuo Ikeda Masahiro Kizaki

To ascertain the exact anti-myeloma mechanism of thalidomide in vivo, we performed structural development studies of thalidomide, and obtained various analogues with specific molecular properties. Among these derivatives, we found that a new thalidomide analogue, 2-(2,6-diisopropylphenyl)-5-hydroxy-1H-isoindole-1,3-dione (5HPP-33) had the most potent anti-myeloma effect and tubulin-polymerizati...

Journal: :Blood 1989
G B Vogelsang A D Hess K J Friedman G W Santos

Chronic graft-v-host disease (GVHD) is the most frequent late complication of allogeneic bone marrow (BM) transplant. To test different treatments, we used a rat model of chronic GVHD which clinically, histologically, and immunologically resembles the disease occurring after human marrow transplant. The following treatments were administered: azathioprine 50 mg/kg/day plus prednisone 1 mg/kg/ev...

Journal: :Blood 2000
S Koc W Leisenring M E Flowers C Anasetti H J Deeg R A Nash J E Sanders R P Witherspoon F R Appelbaum R Storb P J Martin

In a randomized, placebo-controlled, double-blind trial, thalidomide or placebo together with glucocorticoids and either cyclosporine or tacrolimus was administered as initial therapy for clinical extensive chronic graft-versus-host disease (cGVHD). All patients had thrombocytopenia or cGVHD that evolved directly from acute GVHD as an indicator of a poor prognosis. The study drug (thalidomide o...

2010
E. J. Shannon F. G. Sandoval M. J. Morales

One inflammatory event that may be involved in erythema nodosum leprosum (ENL) is the activation of complement, and thalidomide could suppress ENL by inhibiting its activation. To determine if thalidomide inhibits the activation of complement, we first incubated normal serum with Mycobacterium leprae or with zymosan in the presence of thalidomide. Residual functional complement was then determi...

Journal: :Journal of oncology practice 2012
Brian Chen John Restaino LeAnn Norris Sudha Xirasagar Zaina P Qureshi June M McKoy Isaac S Lopez Alyssa Trenery Alanna Murday Adam Kahn Donald R Mattison Paul Ray Oliver Sartor Charles L Bennett

PURPOSE Pharmaceutical safety is a public health issue. In 2005, the Connecticut Attorney General (AG) raised concerns over adverse drug reactions in off-label settings, noting that thalidomide was approved to treat a rare illness, but more than 90% of its use was off label. A hematologist had reported thalidomide with doxorubicin or dexamethasone was associated with venous thromboembolism (VTE...

2005
Alfredo da Matta Gerson Oliveira Penna Celina M. T. Martelli Mariane M. A. Stefani Vanize O. Macedo Maria de Fátima Maroja Aiçar Chaul

BACKGROUND Leprosy remains a public health problem. Episodes of erythema nodosum leprosum (ENL) are acute events that occur before, during and after polychemotherapy. In the last decade, the use of thalidomide as an immunomodulating agent was expanded to other diseases. OBJECTIVES To perform a systematic review of published clinical trials on efficacy and side effects of thalidomide in ENL. To ...

Journal: :Gastroenterology 2011
Zhi-Zheng Ge Hui-Min Chen Yun-Jie Gao Wen-Zhong Liu Chun-Hong Xu Hong-Hong Tan Hai-Ying Chen Wei Wei Jing-Yuan Fang Shu-Dong Xiao

BACKGROUND & AIMS Patients with recurrent bleeding from gastrointestinal vascular malformations are a challenge to treat. We investigated the long-term efficacy and safety of thalidomide for refractory bleeding from gastrointestinal vascular malformations in an open-label, randomized study. METHODS Eligible patients were randomly assigned to groups that were given either 100 mg thalidomide (n...

Journal: :Clinical journal of oncology nursing 2003
Joseph D Tariman

Thalidomide currently is used to treat relapsed and refractory multiple myeloma. The drug also is being actively investigated in patients newly diagnosed with multiple myeloma. The therapeutic applications of thalidomide are expected to grow as clinical trials document its activity in treating other neoplastic disorders and diseases. Healthcare providers need to be well informed of its toxiciti...

Journal: :JAMA 2013
Marzia Lazzerini Stefano Martelossi Giuseppe Magazzù Salvatore Pellegrino Maria Cristina Lucanto Arrigo Barabino Angela Calvi Serena Arrigo Paolo Lionetti Monica Lorusso Francesca Mangiantini Massimo Fontana Giovanna Zuin Gabriella Palla Giuseppe Maggiore Matteo Bramuzzo Maria Chiara Pellegrin Massimo Maschio Vincenzo Villanacci Stefania Manenti Giuliana Decorti Sara De Iudicibus Rossella Paparazzo Marcella Montico Alessandro Ventura

IMPORTANCE Pediatric-onset Crohn disease is more aggressive than adult-onset disease, has high rates of resistance to existing drugs, and can lead to permanent impairments. Few trials have evaluated new drugs for refractory Crohn disease in children. OBJECTIVE To determine whether thalidomide is effective in inducing remission in refractory pediatric Crohn disease. DESIGN, SETTING, AND PATI...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید